Phase III Trial of Transcatheter Arterial Chemoembolization (TACE) Plus Recombinant Human Adenovirus Type 5 Injection for Unresectable Hepatocellular Carcinoma (HCC)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Mar 2019
Price : $35 *
At a glance
- Drugs H-101 (Primary) ; Epirubicin; Lobaplatin; Mitomycin
- Indications Liver cancer
- Focus Therapeutic Use
- 06 Mar 2019 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified Mar 2017)
- 14 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2018.
- 06 Dec 2016 Planned number of patients changed from 120 to 266.